Regeneron announces positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11

Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The trial met its primary endpoint, showing children who added investigational evinacumab to other lipid-lowering therapies reduced their low-density lipoprotein-cholesterol (LDL-C) by an average of 48% at week 24 of the study. Anne C. Goldberg, MD, FNLA, National Lipid Association Chief Science Officer said, “This study highlights the importance of early diagnosis and management of HoFH patients in one of our most vulnerable populations.” To read the full press release, click here.